Protagonist Therapeutics, Inc. (PTGX)
| Market Cap | 6.29B +123.6% |
| Revenue (ttm) | 74.06M -64.4% |
| Net Income | -114.71M |
| EPS | -1.79 |
| Shares Out | 64.31M |
| PE Ratio | n/a |
| Forward PE | 45.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,495 |
| Open | 98.51 |
| Previous Close | 98.85 |
| Day's Range | 97.00 - 100.00 |
| 52-Week Range | 41.29 - 107.84 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 112.62 (+15.07%) |
| Earnings Date | May 5, 2026 |
About PTGX
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class or... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price target is $112.62, which is an increase of 15.07% from the latest price.
News
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
Citizens analyst Jonathan Wolleben raised the firm’s price target on Protagonist Therapeutics (PTGX) to $137 from $120 and keeps an Outperform rating on the shares. Protagonist Therapeutics is expecte...
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $97 and keeps a Neutral rating on the shares. The price target increase is driven mainly
Protagonist Therapeutics management to meet virtually with Clear Street
Virtual Meeting to be held on May 12-13 hosted by Clear Street.
Protagonist Therapeutics participates in a conference call with JPMorgan
Conference call with management will be held on May 6 at 2 pm hosted by JPMorgan.Webcast Link
Protagonist Reports First Quarter 2026 Financial Results and Provides Corporate Update
ICOTYDE™ (icotrokinra) approved by FDA in March for moderate-to-severe plaque psoriasis, triggering a $50 million milestone payment; Protagonist receives tiered royalties of 6% to 10% and is eligible ...
Protagonist exercises right to opt out of 50:50 U.S. arrangement for rusfertide
Protagonist Therapeutics (PTGX) announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its worldwide license and collaboration agreement with
Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration
Opt-out election makes Protagonist eligible for $200 million upon exercise and an additional $200 million upon FDA approval of rusfertide for polycythemia vera Approval would also trigger a $75 millio...
Protagonist Therapeutics Reports Granting of Inducement Awards
NEWARK, CA / ACCESS Newswire / April 16, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on April 15, 2026, it issued inducement awards to two recently hired employees in accor...
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. The firm is citing strong
Protagonist Therapeutics price target raised to $121 from $110 at Truist
Truist analyst Srikripa Devarakonda raised the firm’s price target on Protagonist Therapeutics (PTGX) to $121 from $110 and keeps a Buy rating on the shares. Following J&J’s (JNJ) commentary on
Protagonist Therapeutics price target raised to $116 from $104 at Clear Street
Clear Street analyst Kaveri Pohlman raised the firm’s price target on Protagonist Therapeutics (PTGX) to $116 from $104 and keeps a Buy rating on the shares. Following management meetings, the
Protagonist Announces Presentation of One-Year Phase 3 Data for ICOTYDE(TM) in Moderate-to-Severe Plaque Psoriasis at the 2026 American Academy of Dermatology (AAD) Annual Meeting
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety profile in a once daily pill for moderate-to-severe plaque psoriasis Results fur...
Protagonist price target raised to $110 from $107 at Leerink
Leerink analyst Faisal Khurshid raised the firm’s price target on Protagonist Therapeutics (PTGX) to $110 from $107 and keeps an Outperform rating on the shares. The firm is “impressed” with
Protagonist Therapeutics price target raised to $120 from $112 at Citizens
Citizens raised the firm’s price target on Protagonist Therapeutics (PTGX) to $120 from $112 and keeps an Outperform rating on the shares. The firm says Icotyde’s approval represents a “meaningful
Protagonist Therapeutics price target raised to $112 from $100 at Wedbush
Wedbush raised the firm’s price target on Protagonist Therapeutics (PTGX) to $112 from $100 and keeps an Outperform rating on the shares. The firm believes the FDA approval of Icotyde
Protagonist Therapeutics price target raised to $106 from $95 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Protagonist Therapeutics (PTGX) to $106 from $95 and keeps an Overweight rating on the shares after the company received FDA
Protagonist Therapeutics price target raised to $125 from $115 at Citi
Citi raised the firm’s price target on Protagonist Therapeutics (PTGX) to $125 from $115 and keeps a Buy rating on the shares. The views the FDA approval of Icotyde as
Protagonist Therapeutics price target raised to $119 from $113 at Barclays
Barclays raised the firm’s price target on Protagonist Therapeutics (PTGX) to $119 from $113 and keeps an Overweight rating on the shares. The FDA approved Icotyde for patients with psoriasis
Protagonist Therapeutics price target raised to $104 from $91 at Clear Street
Clear Street raised the firm’s price target on Protagonist Therapeutics (PTGX) to $104 from $91 and keeps a Buy rating on the shares following the FDA approval of icotrokinra for
Protagonist announces Johnson & Johnson received approval for ICOTYDE
Protagonist Therapeutics (PTGX) announced that Johnson & Johnson (JNJ) received FDA approval for ICOTYDE, or icotrokinra, an interleukin-23 receptor antagonist for the treatment of moderate-to-severe ...
Protagonist Therapeutics Transcript: FDA announcement
FDA approved ICOTYDE as the first oral IL-23 receptor blocker for moderate-to-severe plaque psoriasis, supported by robust phase III data and a clean safety profile. The approval triggers significant milestone payments and positions the drug for broad market adoption, with ongoing studies in additional indications and a strong R&D pipeline.
Protagonist Therapeutics Announces U.S. FDA Approval of ICOTYDE(TM) (icotrokinra) for the Treatment of Moderate to Severe Plaque Psoriasis
ICOTYDE is the first and only IL-23R targeted oral peptide that delivers complete skin clearance and a favorable safety profile in a once-daily pill Approval supported by four phase 3 studies that met...
Protagonist Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
The discussion highlighted a robust pipeline of novel oral and injectable peptide therapeutics, with two lead assets nearing potential approval and a diversified R&D focus in immunology, hematology, and obesity. Strategic partnerships and financial strength support continued innovation and market expansion.
Protagonist Therapeutics Transcript: The Citizens Life Sciences Conference 2026
The company leverages deep expertise in peptide therapeutics, with two late-stage partnered assets expected to receive regulatory decisions in Q3. Strong partnerships, a robust pipeline in I&I and obesity, and a solid financial position enable continued innovation and multiple value inflection points in 2026.
Protagonist Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Two partnered products are expected to receive FDA approval in 2026, with significant milestone payments and surplus cash anticipated. The pipeline features first-in-class oral IL-23 and IL-17 assets, innovative obesity candidates, and a robust peptide platform, positioning for market disruption and shareholder value creation.